ABSTRACT
Background Immunizations among vulnerable population, including solid organ transplant recipients (SOT), present suboptimal responses at vaccination and over time. We investigated safety and immunogenicity of the BNT162B2 mRNA COVID-19 vaccine in 34 SOT young adults as compared to 36 healthy controls (HC).
Methods immunogenicity was measured through the analysis of anti SARS-CoV2 IgG Antibodies and antigen specific CD4 T cells (CD40L+), detected by flow cytometry before vaccination, 21 days after priming (T21), 7 days after booster dose (T28) and 2-4 months after priming (T120). Baseline T and B cell immune phenotype was deeply investigated. The safety profile was investigated by close monitoring and self-reported diary.
Results Anti-S and anti-Trimeric Ab responses were significantly lower in SOT vs HC at T21 (p<0.0001) and at T28 (p<0.0001). Ten out of 34 SOT (29%) at T28 and 3 out of 33 (9%) at T120 had undetectable SARS-CoV-2 IgG. The analysis of SARS-CoV-2 specific CD4 T cells showed lower CD40L expression after in vitro stimulation in SOT compared to HC. Lower frequencies of memory B cells were found in patients not responding to vaccination. Lack of seroconversion was higher in patients treated with mycophenolate (p=0.0005). The vaccination was safe and well tolerated. Only short-term adverse events, were reported and no hospitalization or graft rejection were observed after vaccinations.
Conclusions These data show that SOT have a suboptimal immune response following mRNA vaccinations as compared to HC. Alternative strategies should be investigated to improve the immunization against SARS-CoV-2 in these patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was made possible by support from Bambino Gesu Children Hospital through Italian Ministry of Health, ricerca corrente 2020 to NC and ricerca corrente 2019 to PP.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Bambino Gesu' Children's Hospital Ethical Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
AUTHORSHIP NC, PP and PR participated in research design. NC and PP drafted the first version of the manuscript. All Authors participated to the writing of the final version of the paper. CP, EM, AR, DA, CM, LC, MCDA, MR, SZ, CR, SDC, VS, ECM, PZ, CG, SA, RK, CFP, AA and the CONVERS study team participated in the performance of the research. AA, NC, PR and PP acquired funding.
DISCLOSURE The authors declare no competing interests.
FUNDING This work was made possible by support from Bambino Gesù Children’s Hospital through Italian Ministry of Health, ricerca corrente 2020 to NC and ricerca corrente 2019 to PP.
Data Availability
Data used for the submitted paper are available upon request to the Corresponding Author.
ABBREVIATIONS
- Anti-HLA
- anti human leukocyte antigen
- COVID19
- coronavirus disease 2019
- EDTA
- Ethylenediamine tetraacetic acid
- HC
- healthy controls
- IFN
- interferon
- IL2
- interleukin 2
- mRNA
- messenger Ribonucleic Acid
- PBMCs
- Peripheral Blood Mononuclear Cells
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus-2
- SOT
- Solid Organ Transplant Recipients
